{"entity": "journal", "iuid": "e3cced3373784562baf4753f23081bf5", "timestamp": "2026-06-09T03:29:26.517Z", "links": {"self": {"href": "https://publications.scilifelab.se/journal/Acta%20Oncol.json"}, "display": {"href": "https://publications.scilifelab.se/journal/Acta%20Oncol"}}, "title": "Acta Oncol", "issn": "1651-226X", "issn-l": "0284-186X", "publications_count": 7, "publications": [{"entity": "publication", "iuid": "9afbaeee322443f5b2209c9afa15ffc4", "links": {"self": {"href": "https://publications.scilifelab.se/publication/9afbaeee322443f5b2209c9afa15ffc4.json"}, "display": {"href": "https://publications.scilifelab.se/publication/9afbaeee322443f5b2209c9afa15ffc4"}}, "title": "Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2.", "authors": [{"family": "Ginman", "given": "Beatrice", "initials": "B"}, {"family": "Pahnke", "given": "Simon", "initials": "S", "orcid": "0000-0002-3541-2027", "researcher": {"href": "https://publications.scilifelab.se/researcher/0040221ec27a44c4b05b7e886cd48bbb.json"}}, {"family": "Freyhult", "given": "Eva", "initials": "E"}, {"family": "Hoffman", "given": "Tove", "initials": "T"}, {"family": "Kolstad", "given": "Linda", "initials": "L"}, {"family": "R\u00f6nnberg", "given": "Bengt", "initials": "B"}, {"family": "Lundkvist", "given": "\u00c5ke", "initials": "\u00c5"}, {"family": "Hamberg Levedahl", "given": "Kerstin", "initials": "K"}, {"family": "Enblad", "given": "Gunilla", "initials": "G"}, {"family": "Glimelius", "given": "Ingrid", "initials": "I", "orcid": "0000-0001-6158-3041", "researcher": {"href": "https://publications.scilifelab.se/researcher/3db3caec5bef41d2b92cb8e3cf8221ea.json"}}], "type": "journal article", "published": "2023-09-20", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "pages": "1-9", "issn-l": "0284-186X"}, "abstract": "Background: Swedish recommendations to reduce the risk of COVID-19 relied on each citizen's own sense of responsibility rather than mandatory lockdowns. We studied how COVID-19-related self-isolation and anxiety correlated to SARS-CoV-2 seropositivity and PCR-positivity in patients with active cancer treatment.Methods: In a longitudinal cohort study at Uppsala University Hospital patients and cancer personnel were included between April 1st 2020 to August 1st 2020. Serological testing for SARS-CoV-2 was done every 8-12-weeks until 30 March 2021. Patients completed a survey at inclusion regarding self-reported COVID-19-related anxiety and self-isolation.Results: A total of 622 patients [n = 475 with solid malignancies (SM), n = 147 with haematological malignancies (HM)], and 358 healthcare personnel were included. The seropositivity rate was lower for patients than for personnel; 10.5% for SM patients, 6.8% for HM patients, and 16.2% for personnel (p = 0.005). Strict adherence to self-isolation guidelines was reported by 54% of patients but was not associated with a lower risk of becoming seropositive [OR = 1.4 (0.8-2.5), p = 0.2]. High anxiety was expressed by 32% of patients, more often by SM patients than HM patients (34% vs 25% [OR = 1.6 (1.1-2.5, p = 0.03)]). Female gender [OR = 3.5 (2.4-5.2), p < 0.001] and being born outside of Europe [OR = 2.9 (1.4-6.4), p = 0.007] were both associated with high anxiety. Patients reporting high anxiety became seropositive to a similar degree as those with low anxiety [OR = 0.7 (0.3-1.2), p = 0.2]. HM patients with PCR-positive COVID-19 were more likely than SM patients to require oxygen therapy, including non-invasive ventilation/intubation (69% vs. 26%, p = 0.005).Conclusion: For Swedish patients on active cancer treatment, high self-assessed COVID-19-related anxiety or strict adherence to self-isolation guidelines were not associated with a lower risk of COVID-19. Patients with HM were less likely to develop serological antibody response after COVID-19 and were more likely to require advanced hospital care, but expressed less COVID-19-related anxiety than patients with SM.", "doi": "10.1080/0284186X.2023.2257873", "pmid": "37729083", "labels": {"Bioinformatics Support and Infrastructure": "Collaborative", "Bioinformatics Support, Infrastructure and Training": "Collaborative", "Bioinformatics (NBIS)": "Collaborative"}, "xrefs": [], "notes": [], "created": "2023-11-16T12:20:43.626Z", "modified": "2023-11-16T12:20:43.691Z"}, {"entity": "publication", "iuid": "e335b68f25c64535bff7e2b859d6c729", "links": {"self": {"href": "https://publications.scilifelab.se/publication/e335b68f25c64535bff7e2b859d6c729.json"}, "display": {"href": "https://publications.scilifelab.se/publication/e335b68f25c64535bff7e2b859d6c729"}}, "title": "Ki67 and prostate specific antigen are prognostic in metastatic hormone na\u00efve prostate cancer.", "authors": [{"family": "Spyratou", "given": "Vasiliki", "initials": "V"}, {"family": "Freyhult", "given": "Eva", "initials": "E"}, {"family": "Bergh", "given": "Anders", "initials": "A"}, {"family": "Thellenberg-Karlsson", "given": "Camilla", "initials": "C"}, {"family": "Wikstr\u00f6m", "given": "Pernilla", "initials": "P"}, {"family": "Wel\u00e9n", "given": "Karin", "initials": "K", "orcid": "0000-0001-6480-636X", "researcher": {"href": "https://publications.scilifelab.se/researcher/2212e6a5c0b844908cbce508027c2a54.json"}}, {"family": "Josefsson", "given": "Andreas", "initials": "A"}], "type": "journal article", "published": "2023-09-15", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "pages": "1-9", "issn-l": "0284-186X"}, "abstract": "For metastatic hormone na\u00efve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, de-escalation is preferable to avoid unnecessary side effects, especially from docetaxel, but markers to identify these patients are lacking. The purpose of the present study was to investigate the potential of PSA and Ki67 immunoreactive scores as prognostic and treatment-predictive markers.\n\nProstate biopsies from 92 patients with metastatic hormone na\u00efve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performed with Clariom D microarrays to identify the phenotypic profile associated with the immunohistochemistry scores of biopsies. Cox regression analysis for progression free survival after ADT adjustment for age, ISUP, and serum PSA and Kaplan-Meier analyses were performed to assess prognostic values of Ki67, PSA, and the Ki67/PSA ratio.\n\nThe immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognostic value than Ki67 itself. Further, mRNA expression data analysis showed an association between high Ki67/PSA ratio, cell-cycle regulation, and DNA damage repair. In an exploratory sub-analysis of 12 patients treated with early docetaxel as addition to ADT and matched controls, a high Ki67/PSA ratio showed potential to identify those who benefit from docetaxel.\n\nPSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.", "doi": "10.1080/0284186X.2023.2254480", "pmid": "37713321", "labels": {"Bioinformatics Support and Infrastructure": "Collaborative", "Bioinformatics Support, Infrastructure and Training": "Collaborative", "Bioinformatics (NBIS)": "Collaborative"}, "xrefs": [], "notes": [], "created": "2023-11-16T12:13:26.712Z", "modified": "2023-11-16T12:13:26.751Z"}, {"entity": "publication", "iuid": "c40979f92a89455089e719388c906c31", "links": {"self": {"href": "https://publications.scilifelab.se/publication/c40979f92a89455089e719388c906c31.json"}, "display": {"href": "https://publications.scilifelab.se/publication/c40979f92a89455089e719388c906c31"}}, "title": "The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results.", "authors": [{"family": "Smedby", "given": "K E", "initials": "KE"}, {"family": "W\u00e4sterlid", "given": "T", "initials": "T"}, {"family": "Tham", "given": "E", "initials": "E"}, {"family": "Haider", "given": "Z", "initials": "Z"}, {"family": "Joelsson", "given": "J", "initials": "J"}, {"family": "Thorvaldsdottir", "given": "B", "initials": "B"}, {"family": "Krstic", "given": "A", "initials": "A"}, {"family": "Wahlin", "given": "B E", "initials": "BE", "orcid": "0000-0003-3566-8847", "researcher": {"href": "https://publications.scilifelab.se/researcher/9c586ece98fe4a6b8b4f900a934d0942.json"}}, {"family": "Foroughi-Asl", "given": "H", "initials": "H"}, {"family": "Karlsson", "given": "C", "initials": "C"}, {"family": "Eloranta", "given": "S", "initials": "S"}, {"family": "Saft", "given": "L", "initials": "L"}, {"family": "Palma", "given": "M", "initials": "M"}, {"family": "Kwiecinska", "given": "A", "initials": "A"}, {"family": "Hansson", "given": "L", "initials": "L"}, {"family": "\u00d6sterborg", "given": "A", "initials": "A"}, {"family": "Wirta", "given": "V", "initials": "V"}, {"family": "Rassidakis", "given": "G", "initials": "G"}, {"family": "Sander", "given": "B", "initials": "B"}, {"family": "Sonnevi", "given": "K", "initials": "K"}, {"family": "Rosenquist", "given": "R", "initials": "R"}], "type": "journal article", "published": "2023-06-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "issn-l": "0284-186X", "volume": "62", "issue": "6", "pages": "560-564"}, "abstract": null, "doi": "10.1080/0284186X.2023.2218556", "pmid": "37415362", "labels": {"Clinical Genomics Stockholm": "Service", "Clinical Genomics": "Service"}, "xrefs": [], "notes": [], "created": "2023-11-22T21:49:03.180Z", "modified": "2024-11-20T20:05:16.410Z"}, {"entity": "publication", "iuid": "e80c590ff50e4d539845ffae17d694e5", "links": {"self": {"href": "https://publications.scilifelab.se/publication/e80c590ff50e4d539845ffae17d694e5.json"}, "display": {"href": "https://publications.scilifelab.se/publication/e80c590ff50e4d539845ffae17d694e5"}}, "title": "PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.", "authors": [{"family": "Abdulla", "given": "Maysaa", "initials": "M"}, {"family": "Alexsson", "given": "Andrei", "initials": "A"}, {"family": "Sundstr\u00f6m", "given": "Christer", "initials": "C"}, {"family": "Ladenvall", "given": "Claes", "initials": "C"}, {"family": "Mansouri", "given": "Larry", "initials": "L"}, {"family": "Lindskog", "given": "Cecilia", "initials": "C"}, {"family": "Berglund", "given": "Mattias", "initials": "M"}, {"family": "Cavelier", "given": "Lucia", "initials": "L"}, {"family": "Enblad", "given": "Gunilla", "initials": "G", "orcid": "0000-0002-0594-724X", "researcher": {"href": "https://publications.scilifelab.se/researcher/11313af3f4a241ecb93af23ab2652195.json"}}, {"family": "Hollander", "given": "Peter", "initials": "P"}, {"family": "Amini", "given": "Rose-Marie", "initials": "RM", "orcid": "0000-0003-0901-5252", "researcher": {"href": "https://publications.scilifelab.se/researcher/c157abcd61fa4900b5ad502b408d6d95.json"}}], "type": "journal article", "published": "2021-04-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "issn-l": "0284-186X", "volume": "60", "issue": "4", "pages": "531-538"}, "abstract": "Programmed cell death 1 (PD-1) and its ligands PD-L1 and PD-L2, as well as Indoleamine 2,3-deoxygenase (IDO1) can be expressed both by tumor and microenvironmental cells and are crucial for tumor immune escape. We aimed to evaluate the role of PD-1, its ligands and IDO1 in a cohort of patients with primary diffuse large B-cell lymphoma of the CNS (PCNSL).\n\nTissue microarrays (TMAs) were constructed in 45 PCNSL cases. RNA extraction from whole tissue sections and RNA sequencing were successfully performed in 33 cases. Immunohistochemical stainings for PD-1, PD-L1/paired box protein 5 (PAX-5), PD-L2/PAX-5 and IDO1, and Epstein-Barr virus encoding RNA (EBER) in situ hybridization were analyzed.\n\nHigh proportions of PD-L1 and PD-L2 positive tumor cells were observed in 11% and 9% of cases, respectively. High proportions of PD-L1 and PD-L2 positive leukocytes were observed in 55% and 51% of cases, respectively. RNA sequencing revealed that gene expression of IDO1 was high in patients with high proportion of PD-L1 positive leukocytes (p = .01). Protein expression of IDO1 in leukocytes was detected in 14/45 cases, in 79% of these cases a high proportion of PD-L1 positive leukocytes was observed. Gene expression of IDO1 was high in EBER-positive cases (p = .0009) and protein expression of IDO1 was detected in five of six EBER-positive cases.\n\nOur study shows a significant association between gene and protein expression of IDO1 and protein expression of PD-L1 in the tumor microenvironment of PCNSL, possibly of importance for prediction of response to immunotherapies.", "doi": "10.1080/0284186X.2021.1881161", "pmid": "33579170", "labels": {"Clinical Genomics Uppsala": "Service", "National Genomics Infrastructure": "Service", "NGI Uppsala (SNP&SEQ Technology Platform)": "Service", "Clinical Genomics": "Service"}, "xrefs": [], "notes": [], "created": "2021-12-06T08:28:38.570Z", "modified": "2023-06-20T15:58:18.800Z"}, {"entity": "publication", "iuid": "f2317acce3bc4c839fb919d77f6e0a01", "links": {"self": {"href": "https://publications.scilifelab.se/publication/f2317acce3bc4c839fb919d77f6e0a01.json"}, "display": {"href": "https://publications.scilifelab.se/publication/f2317acce3bc4c839fb919d77f6e0a01"}}, "title": "Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.", "authors": [{"family": "Nunes", "given": "Lu\u00eds", "initials": "L", "orcid": "0000-0002-3391-1607", "researcher": {"href": "https://publications.scilifelab.se/researcher/9be3293494cd4efe9bab07504cc1fcd0.json"}}, {"family": "Aaseb\u00f8", "given": "Kristine", "initials": "K", "orcid": "0000-0003-3575-5588", "researcher": {"href": "https://publications.scilifelab.se/researcher/d615e45a5b3340a79d3bd16c921c2ce2.json"}}, {"family": "Mathot", "given": "Lucy", "initials": "L", "orcid": "0000-0002-2990-2038", "researcher": {"href": "https://publications.scilifelab.se/researcher/c9f3bfe35ddf41e5beb4312d3408a7ea.json"}}, {"family": "Ljungstr\u00f6m", "given": "Viktor", "initials": "V"}, {"family": "Edqvist", "given": "Per-Henrik", "initials": "PH"}, {"family": "Sundstr\u00f6m", "given": "Magnus", "initials": "M"}, {"family": "Dragomir", "given": "Anca", "initials": "A", "orcid": "0000-0003-2777-8114", "researcher": {"href": "https://publications.scilifelab.se/researcher/da4c734efcc240d589dc5c99a433d904.json"}}, {"family": "Pfeiffer", "given": "Per", "initials": "P"}, {"family": "Ameur", "given": "Adam", "initials": "A", "orcid": "0000-0001-6085-6749", "researcher": {"href": "https://publications.scilifelab.se/researcher/e960811513664a78b2804a00ee70f7c3.json"}}, {"family": "Ponten", "given": "Fredrik", "initials": "F", "orcid": "0000-0003-0703-3940", "researcher": {"href": "https://publications.scilifelab.se/researcher/a8b56979a6c74891aa277fb28848b6ce.json"}}, {"family": "Mezheyeuski", "given": "Artur", "initials": "A", "orcid": "0000-0002-4394-2634", "researcher": {"href": "https://publications.scilifelab.se/researcher/dd907ed1df0441b99789d3e045c4d890.json"}}, {"family": "Sorbye", "given": "Halfdan", "initials": "H"}, {"family": "Sj\u00f6blom", "given": "Tobias", "initials": "T", "orcid": "0000-0001-6668-4140", "researcher": {"href": "https://publications.scilifelab.se/researcher/909f00a5bf6e465f9ff560b12bcd863a.json"}}, {"family": "Glimelius", "given": "Bengt", "initials": "B", "orcid": "0000-0002-5440-791X", "researcher": {"href": "https://publications.scilifelab.se/researcher/4e79e661083f49bf90cbbfc19670f404.json"}}], "type": "journal article", "published": "2020-04-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "volume": "59", "issue": "4", "pages": "417-426", "issn-l": "0284-186X"}, "abstract": "Background: We have reported that BRAF V600E mutations and microsatellite instability-high (MSI-H) are more prevalent in a population-based cohort of metastatic colorectal cancer (mCRC) patients than has been reported from clinical trials or hospital-based patient groups. The aim was to explore if other mutations in mCRC differ in prevalence between these cohorts in relation to mismatch repair status and primary tumor location and if presence of bone or brain metastases is associated with any mutations.Material and methods: A population-based cohort of 798 mCRC patients from three regions in Scandinavia was used. Forty-four cancer related genes were investigated in a custom designed Ampliseq hotspot panel. Differences in survival were analyzed using the Kaplan-Meier estimator and the Cox regression analysis.Results: Determination of mutations was possible in 449/501 patients for 40/44 genes. Besides BRAF V600E, seen in 19% of the tumors, none of the other mutations appeared more prevalent than in trial cohorts. BRAF V600E and MSI-H, seen in 8%, were associated with poor prognosis as was right-sided primary tumor location (39%) when compared to left-sided and rectum together; however, in a multivariable regression, only the BRAF mutation retained its statistical significance. No other mutations were associated with poor prognosis. ERBB2 alterations were more common if bone metastases were present at diagnosis (17% vs. 4%, p = .011). No association was found for brain metastases. Fifty-two percent had an alteration that is treatable with an FDA-approved targeted therapy, chiefly by EGFR-inhibitor for RAS wild-type and a check-point inhibitor for MSI-H tumors.Conclusions: Right-sided tumor location, BRAF V600E mutations, but no other investigated mutation, and MSI-H are more commonly seen in an unselected cohort than is reported from clinical patient cohorts, likely because they indicate poor prognosis. Half of the patients have a tumor that is treatable with an already FDA-approved targeted drug for mCRC.", "doi": "10.1080/0284186X.2019.1711169", "pmid": "31924107", "labels": {"National Genomics Infrastructure": "Collaborative", "NGI Uppsala (Uppsala Genome Center)": "Collaborative", "Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [], "notes": [], "created": "2020-02-11T10:07:57.408Z", "modified": "2024-01-16T13:48:42.696Z"}, {"entity": "publication", "iuid": "1e351a85bfb04fa393f09111089cedd1", "links": {"self": {"href": "https://publications.scilifelab.se/publication/1e351a85bfb04fa393f09111089cedd1.json"}, "display": {"href": "https://publications.scilifelab.se/publication/1e351a85bfb04fa393f09111089cedd1"}}, "title": "U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.", "authors": [{"family": "Glimelius", "given": "Bengt", "initials": "B"}, {"family": "Melin", "given": "Beatrice", "initials": "B"}, {"family": "Enblad", "given": "Gunilla", "initials": "G"}, {"family": "Alafuzoff", "given": "Irina", "initials": "I"}, {"family": "Beskow", "given": "Anna", "initials": "A"}, {"family": "Ahlstr\u00f6m", "given": "H\u00e5kan", "initials": "H"}, {"family": "Bill-Axelson", "given": "Anna", "initials": "A"}, {"family": "Birgisson", "given": "Helgi", "initials": "H"}, {"family": "Bj\u00f6r", "given": "Ove", "initials": "O"}, {"family": "Edqvist", "given": "Per-Henrik", "initials": "PH"}, {"family": "Hansson", "given": "Tony", "initials": "T"}, {"family": "Helleday", "given": "Thomas", "initials": "T", "orcid": "0000-0002-7384-092X", "researcher": {"href": "https://publications.scilifelab.se/researcher/3d7256c271ea4adea404d4ff355f804e.json"}}, {"family": "Hellman", "given": "Per", "initials": "P"}, {"family": "Henriksson", "given": "Kerstin", "initials": "K"}, {"family": "Hesselager", "given": "G\u00f6ran", "initials": "G"}, {"family": "Hultdin", "given": "Magnus", "initials": "M"}, {"family": "H\u00e4ggman", "given": "Michael", "initials": "M"}, {"family": "H\u00f6glund", "given": "Martin", "initials": "M"}, {"family": "Jonsson", "given": "H\u00e5kan", "initials": "H"}, {"family": "Larsson", "given": "Chatarina", "initials": "C"}, {"family": "Lindman", "given": "Henrik", "initials": "H"}, {"family": "Ljuslinder", "given": "Ingrid", "initials": "I"}, {"family": "Mindus", "given": "Stephanie", "initials": "S"}, {"family": "Nygren", "given": "Peter", "initials": "P"}, {"family": "Pont\u00e9n", "given": "Fredrik", "initials": "F"}, {"family": "Riklund", "given": "Katrine", "initials": "K"}, {"family": "Rosenquist", "given": "Richard", "initials": "R"}, {"family": "Sandin", "given": "Fredrik", "initials": "F"}, {"family": "Schwenk", "given": "Jochen M", "initials": "JM", "orcid": "0000-0001-8141-8449", "researcher": {"href": "https://publications.scilifelab.se/researcher/aba5822711b246b397fffacb7ae403b3.json"}}, {"family": "Stenling", "given": "Roger", "initials": "R"}, {"family": "St\u00e5lberg", "given": "Karin", "initials": "K"}, {"family": "St\u00e5lberg", "given": "Peter", "initials": "P"}, {"family": "Sundstr\u00f6m", "given": "Christer", "initials": "C"}, {"family": "Thellenberg Karlsson", "given": "Camilla", "initials": "C"}, {"family": "Westermark", "given": "Bengt", "initials": "B"}, {"family": "Bergh", "given": "Anders", "initials": "A"}, {"family": "Claesson-Welsh", "given": "Lena", "initials": "L"}, {"family": "Palmqvist", "given": "Richard", "initials": "R", "orcid": "0000-0002-9933-2843", "researcher": {"href": "https://publications.scilifelab.se/researcher/40ae823e5364458b8f957a65a82c741f.json"}}, {"family": "Sj\u00f6blom", "given": "Tobias", "initials": "T"}], "type": "journal article", "published": "2018-02-00", "journal": {"title": "Acta Oncol", "issn": "1651-226X", "volume": "57", "issue": "2", "pages": "187-194", "issn-l": "0284-186X"}, "abstract": "Progress in cancer biomarker discovery is dependent on access to high-quality biological materials and high-resolution clinical data from the same cases. To overcome current limitations, a systematic prospective longitudinal sampling of multidisciplinary clinical data, blood and tissue from cancer patients was therefore initiated in 2010 by Uppsala and Ume\u00e5 Universities and involving their corresponding University Hospitals, which are referral centers for one third of the Swedish population.\n\nPatients with cancer of selected types who are treated at one of the participating hospitals are eligible for inclusion. The healthcare-integrated sampling scheme encompasses clinical data, questionnaires, blood, fresh frozen and formalin-fixed paraffin-embedded tissue specimens, diagnostic slides and radiology bioimaging data.\n\nIn this ongoing effort, 12,265 patients with brain tumors, breast cancers, colorectal cancers, gynecological cancers, hematological malignancies, lung cancers, neuroendocrine tumors or prostate cancers have been included until the end of 2016. From the 6914 patients included during the first five years, 98% were sampled for blood at diagnosis, 83% had paraffin-embedded and 58% had fresh frozen tissues collected. For Uppsala County, 55% of all cancer patients were included in the cohort.\n\nClose collaboration between participating hospitals and universities enabled prospective, longitudinal biobanking of blood and tissues and collection of multidisciplinary clinical data from cancer patients in the U-CAN cohort. Here, we summarize the first five years of operations, present U-CAN as a highly valuable cohort that will contribute to enhanced cancer research and describe the procedures to access samples and data.", "doi": "10.1080/0284186X.2017.1337926", "pmid": "28631533", "labels": {"Tissue Profiling": "Collaborative"}, "xrefs": [], "notes": [], "created": "2017-11-05T12:44:17.303Z", "modified": "2021-07-08T13:01:30.754Z"}, {"entity": "publication", "iuid": "de4b6eb652804a01a00ed66e7f961b23", "links": {"self": {"href": "https://publications.scilifelab.se/publication/de4b6eb652804a01a00ed66e7f961b23.json"}, "display": {"href": "https://publications.scilifelab.se/publication/de4b6eb652804a01a00ed66e7f961b23"}}, "title": "FGF2 as a potential prognostic biomarker for proneural glioma patients.", "authors": [{"family": "Sooman", "given": "Linda", "initials": "L"}, {"family": "Freyhult", "given": "Eva", "initials": "E"}, {"family": "Jaiswal", "given": "Archita", "initials": "A"}, {"family": "Navani", "given": "Sanjay", "initials": "S"}, {"family": "Edqvist", "given": "Per-Henrik", "initials": "PH"}, {"family": "Pont\u00e9n", "given": "Fredrik", "initials": "F"}, {"family": "Tchougounova", "given": "Elena", "initials": "E"}, {"family": "Smits", "given": "Anja", "initials": "A"}, {"family": "Elsir", "given": "Tamador", "initials": "T"}, {"family": "Gullbo", "given": "Joachim", "initials": "J"}, {"family": "Lennartsson", "given": "Johan", "initials": "J"}, {"family": "Bergqvist", "given": "Michael", "initials": "M"}, {"family": "Ekman", "given": "Simon", "initials": "S"}], "type": "journal article", "published": "2015-03-00", "journal": {"volume": "54", "issn": "1651-226X", "issue": "3", "pages": "385-394", "title": "Acta Oncol", "issn-l": "0284-186X"}, "abstract": "The survival of high-grade glioma patients is poor and the treatment of these patients can cause severe side effects. This fosters the necessity to identify prognostic biomarkers, in order to optimize treatment and diminish unnecessary suffering of patients. The aim of this study was to identify prognostic biomarkers for high-grade glioma patients.\n\nEleven proteins were selected for analysis due to their suggested importance for survival of patients with other types of cancers and due to a high variation in protein levels between glioma patients (according to the Human Protein Atlas, www.proteinatlas.org). Protein expression patterns of these 11 proteins were analyzed by immunohistochemistry in tumor samples from 97 high-grade glioma patients. The prognostic values of the proteins were analyzed with univariate and multivariate Cox regression analyses for the high-grade glioma patients, including subgroup analyses of histological subtypes and immunohistochemically defined molecular subtypes.\n\nThe proteins with the most significant (univariate and multivariate p<0.05) correlations were analyzed further with cross-validated Kaplan-Meier analyses for the possibility of predicting survival based on the protein expression pattern of the corresponding candidate. Random Forest classification with variable subset selection was used to analyze if a protein signature consisting of any combination of the 11 proteins could predict survival for the high-grade glioma patients and the subgroup with glioblastoma patients. The proteins which correlated most significantly (univariate and multivariate p<0.05) to survival in the Cox regression analyses were Myc for all high-grade gliomas and FGF2, CA9 and CD44 for the subgroup of proneural gliomas, with FGF2 having a strong negative predictive value for survival. No prognostic signature of the proteins could be found.\n\nFGF2 is a potential prognostic biomarker for proneural glioma patients, and warrants further investigation.", "doi": "10.3109/0284186X.2014.951492", "pmid": "25263081", "labels": {"Tissue Profiling": null, "Bioinformatics Support and Infrastructure": null, "Bioinformatics Support, Infrastructure and Training": null, "Bioinformatics (NBIS)": null}, "xrefs": [], "notes": [], "created": "2017-05-02T12:58:37.514Z", "modified": "2020-01-21T13:53:20.922Z"}], "created": "2017-05-09T09:12:39.473Z", "modified": "2020-11-27T13:14:06.289Z"}